CHCWM – Cancer & Hematology Centers of West Michigan

Seattle Genetics (ECHELON-3)

A Randomized, Double-blind, Placebo-Controlled, Active-Comparator, Multicenter, Phase 3 Study of Brentuximab Vedotin or Placebo in Combination With Lenalidomide and Rituximab in Subjects with Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)

Principal Investigator: Dr. Erin Pettijohn

For more information on this trial, read its profile on clinicaltrials.gov here.